YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* Steven Sangha has entered into a voting and support agreement [https://seekingalpha.com/pr/20648651-steven-sangha-announces-voting-and-support-agreement-for-sernova-biotherapeutics-inc-s] with Seraxis Holdings to support its proposed acq…
Issued on behalf of Avaí Bio, Inc. (OTCQB: AVAI) LAS VEGAS, July 21, 2026 /PRNewswire/ -- (American News Group News Commentary) For the millions of people who manage diabetes with daily insulin injections, the holy grail has always been th…
* Sernova Biotherapeutics (SVA:CA [https://seekingalpha.com/symbol/SVA:CA]) (OTC: SEOVF [https://seekingalpha.com/symbol/SEOVF]) said on Friday it plans to amend certain outstanding warrants, subject to approval from the TSX. * The company…
LONDON, Ontario and WINDHAM COUNTY, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced the U.S. Food and Drug Administra…
LONDON, Ontario and WINDHAM COUNTY, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced an update on its conformal coatin…
All six patients in the first cohort (Cohort A) were successfully implanted with the 8-channel Cell Pouch System with post-transplant follow-up periods ranging from 6 months to 3.5 years;5 of 6 patients in Cohort A discontinued insulin the…
Dr. Piotr Witkowski presenting new data from ongoing Phase 1/2 clinical trial of the Cell Pouch System™ in patients with type 1 diabetes (T1D) Dr. Alice Tomei presenting preclinical data on transplantation of conformal coated islet cells i…
LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced new preclinical data for its nov…
- Introduction of New CEO Cynthia Pussinen and Recently Appointed Chief Business Officer, Dr. Modestus Obochi, on September 15, 2023 - - Business Update, Strategy & Outlook Call on October 5, 2023 - LONDON, Ontario and WINDHAM COUNTY, Conn…
LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today provided a development update on its exclu…
Industry veteran with deep commercial experience joins to lead the next stage of growth and development Dr. Philip Toleikis will serve as Chief Technology Officer Sernova to host investor calls LONDON, Ontario and WINDHAM COUNTY, Conn., Se…
Sernova Corp. LONDON, Ontario, July 26, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, today announced the appointment of Modestus Obochi, Ph.D.,…
LONDON, Ontario, July 26, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, today announced the appointment of Modestus Obochi, Ph.D., MBA, a vetera…
Sernova Corp. In the first cohort of the ongoing Phase 1/2 clinical trial, the first 5 patients to complete protocol-defined islet transplants achieved insulin-independence for ongoing periods of 6 to 38 months. Following islet transplants…
In the first cohort of the ongoing Phase 1/2 clinical trial, the first 5 patients to complete protocol-defined islet transplants achieved insulin-independence for ongoing periods of 6 to 38 months.Following islet transplants to the 8-chann…
Sernova Corp. Company to host in-person only analyst and investor event at an offsite location following the presentation on Saturday, June 24 at the ADA Scientific Sessions LONDON, Ontario, June 22, 2023 (GLOBE NEWSWIRE) -- Sernova Corp.…
LONDON, Ontario, June 22, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, will be presenting updated interim data from its ongoing Phase 1/2 clini…
Sernova Corp. LONDON, Ontario, June 16, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be participating in the upcoming symp…
LONDON, Ontario, June 16, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be participating in the upcoming symposia-cel Truis…
Sernova Corp. LONDON, Ontario, May 31, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, today announced the outcomes from a strategic and executive…
LONDON, Ontario, May 31, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, today announced the outcomes from a strategic and executive leadership re…
Sernova Corp. LONDON, Ontario, May 03, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research col…
LONDON, Ontario, May 03, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research collaboration wit…
TORONTO, April 25, 2023 /CNW/ - The group of longstanding shareholders (the "Concerned Shareholders") of Sernova Corp (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH) (XETRA: PSH) ("Sernova" or the "Company") wishes to thank all shareholders for their…
Sernova Corp. Evotec’s scalable GMP manufacturing process has been designed to produce induced pluripotent stem cell (iPSC)-derived islet-like clusters (ILCs) with high insulin-producing beta cell content as well as glucagon and somatostat…
Evotec’s scalable GMP manufacturing process has been designed to produce induced pluripotent stem cell (iPSC)-derived islet-like clusters (ILCs) with high insulin-producing beta cell content as well as glucagon and somatostatin (produced b…
Sernova Corp. Following Institutional Shareholder Services’ positive recommendations, Glass Lewis is the second independent, third-party proxy advisory firm to recommend Sernova’s shareholders vote FOR all management’s director nominees us…
Following Institutional Shareholder Services’ positive recommendations, Glass Lewis is the second independent, third-party proxy advisory firm to recommend Sernova’s shareholders vote FOR all management’s director nominees using ONLY manag…
TORONTO, April 17, 2023 /CNW/ - The group of longstanding shareholders (the "Concerned Shareholders") of Sernova Corp (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH) (XETRA: PSH) ("Sernova" or the "Company") maintains that the decrease in share valua…
Sernova Corp. ISS, an independent, third-party proxy advisory firm, recommends Sernova’s shareholders vote FOR all management’s director nominees using ONLY management’s WHITE proxy. ISS notes the dissidents failed to present a detailed ex…
ISS, an independent, third-party proxy advisory firm, recommends Sernova’s shareholders vote FOR all management’s director nominees using ONLY management’s WHITE proxy.ISS notes the dissidents failed to present a detailed explanation of th…
Sernova Corp. ISS, an independent, third-party proxy advisory firm, recommends Sernova’s shareholders vote FOR all management’s director nominees using ONLY management’s WHITE proxy. ISS notes the dissidents failed to present a detailed ex…
ISS, an independent, third-party proxy advisory firm, recommends Sernova’s shareholders vote FOR all management’s director nominees using ONLY management’s WHITE proxy.ISS notes the dissidents failed to present a detailed explanation of th…
LONDON, Ontario, April 10, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced that President and Chief Executive Officer, Dr. Philip Tol…
Sernova Corp. LONDON, Ontario, April 10, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced that President and Chief Executive Officer,…
The dissident director nominees declined to follow proper protocol to participate in Sernova’s board renewal process and instead are imposing themselves on the Company through a costly and disruptive proxy battleManagement and the Board ha…